# US 2026/0097013 A1 · Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0097013 A1
- Document ID: US20260097013A1
- Status: Published application
- Kind: A1
- Application number: 19/235,544
- Filed: 2025-06-11
- Published: 2026-04-09
- Earliest claimed: 2016-01-11
- Assignees: EpicentRx, Inc.
- Applicants: EpicentRx, Inc.
- Inventors: Bryan T. ORONSKY; Jan SCICINSKI; Scott CAROEN
- Web page: https://patentgrep.com/patent/US20260097013A1

## CPC

- A61K 31/397: having four-membered rings, e.g. azetidine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/727: Heparin; Heparan
- A61K 35/14: Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42)
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 47/46: Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl) ethanone (ABDNAZ), including formulations containing autologous whole blood and ABDNAZ that can be rapidly administered to a patient by intravenous infusion without any significant pain at the site of infusion.

## Claims

### Claim 1

A method for intravenous administration of an ABDNAZ formulation to a patient suffering from cancer in order to treat the cancer, comprising intravenously administering to the patient in need thereof a therapeutically effective amount of an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant, in order to treat the cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the whole blood is autologous whole blood.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 5 mL/hour.

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 10 mL/hour.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is a solid tumor.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.

### Claim 7 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is brain cancer.

### Claim 8 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is colorectal cancer.

### Claim 9 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is cholangiocarcinoma or lung cancer.

### Claim 10 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is a leukemia or lymphoma.

### Claim 11 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the cancer is a B-cell lymphoma or non-Hodgkin lymphoma.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 1.

### Claim 14

A method for rapid intravenous administration of an ABDNAZ formulation to a patient while minimizing injection site pain experienced by the patient, comprising intravenously administering to the patient at a rate of at least 10 mL/hour an ABDNAZ formulation comprising whole blood, ABDNAZ, and an anticoagulant, wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 2.

### Claim 15 (depends on 14)

The method of claim 14, wherein any pain experienced by the patient at the site of intravenous administration of the ABDNAZ formulation due to intravenous administration of the ABDNAZ formulation is no greater than Grade 1.

### Claim 16 (depends on 14, 15)

The method of claim 14 or 15, wherein the patient is suffering from cancer.

### Claim 17 (depends on 16)

The method of claim 16, wherein the cancer is a solid tumor.

### Claim 18 (depends on 16)

The method of claim 16, wherein the cancer is brain cancer, bladder cancer, breast cancer, cervical cancer, cholangiocarcinoma, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, lung cancer, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, or uterine cancer.

### Claim 19 (depends on 16)

The method of claim 16, wherein the cancer is brain cancer.

### Claim 20 (depends on 16)

The method of claim 16, wherein the cancer is colorectal cancer.

### Claim 21 (depends on 16)

The method of claim 16, wherein the cancer is cholangiocarcinoma or lung cancer.

### Claim 22 (depends on 16)

The method of claim 16, wherein the cancer is a leukemia or lymphoma.

### Claim 23 (depends on 16)

The method of claim 16, wherein the cancer is a B-cell lymphoma or non-Hodgkin lymphoma.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 30 mL/hour.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 60 mL/hour.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 90 mL/hour.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 120 mL/hour.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 200 mL/hour.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the ABDNAZ formulation is intravenously administered to the patient at a rate of at least 300 mL/hour.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 10 μg/mL.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 20 μg/mL.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 50 μg/mL.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 100 μg/mL.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 150 μg/mL.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 1 mg/mL.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 0.5 mg/mL.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 250 μg/mL.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 20 μg/mL to about 200 μg/mL.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNAZ formulation consists essentially of whole blood, ABDNAZ, and an anticoagulant.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol, and N,N-dimethylacetamide.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, and optionally one or more of water, a polyethylene glycol having a number average molecular weight in the range of about 200 g/mol to about 600 g/mol, and N,N-dimethylacetamide.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number average molecular weight in the range of about 200 g/mol to about 600 g/mol, and N,N-dimethylacetamide.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNA′Z formulation consists of whole blood, ABDNA′Z, an anticoagulant, and optionally one or more of water, a polyethylene glycol having a number average molecular weight of about 400 g/mol, and N,N-dimethylacetamide.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 1-38, wherein the ABDNAZ formulation consists of whole blood, ABDNAZ, an anticoagulant, water, a polyethylene glycol having a number average molecular weight of about 400 g/mol, and N,N-dimethylacetamide.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the anticoagulant comprises one or more of heparin and a citrate salt.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, wherein the anticoagulant is a solution comprising an alkali metal citrate salt, dextrose, and water.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, wherein the anticoagulant is present in the ABDNAZ formulation in an amount ranging from about 0.1% wt/wt to about 15% w/w.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes at least 30% wt/wt of the ABDNAZ formulation.

### Claim 49 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes at least 60% wt/wt of the ABDNAZ formulation.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes at least 75% wt/wt of the ABDNAZ formulation.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes at least 90% wt/wt of the ABDNA′Z formulation.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes from about 60% wt/wt to about 99% wt/wt of the ABDNAZ formulation.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes from about 70% wt/wt to about 95% wt/wt of the ABDNAZ formulation.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, wherein the whole blood constitutes from about 75% wt/wt to about 90% wt/wt of the ABDNAZ formulation.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein there is from about 90 mL to about 110 mL of whole blood in the ABDNAZ formulation.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein there is from about 95 mL to about 105 mL of whole blood in the ABDNAZ formulation.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein there is about 100 mL of whole blood in the ABDNAZ formulation.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein there is about 10 mL to about 20 mL of whole blood in the ABDNAZ formulation.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein there is about 10 mL of whole blood in the ABDNAZ formulation.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 50 mL to about 200 mL.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 75 mL to about 150 mL.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 90 mL to about 140 mL.

### Claim 63 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 100 mL to about 140 mL.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 100 mL to about 120 mL.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the ABDNAZ formulation has a volume in the range of about 10 mL to about 20 mL.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ formulation commences within about 1 hour after formation of the ABDNAZ formulation.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ formulation commences within about 30 minutes after formation of the ABDNAZ formulation.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein intravenous administration of the ABDNAZ formulation commences within about 20 minutes after formation of the ABDNAZ formulation.

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 1-68, wherein intravenous administration of the ABDNAZ formulation is complete within about 6 hours after formation of the ABDNAZ formulation.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 1-68, wherein intravenous administration of the ABDNAZ formulation is complete within about 4 hours after formation of the ABDNAZ formulation.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 1-70, further comprising obtaining an aliquot of whole blood from the patient, and then using said aliquot to prepare the ABDNAZ formulation for administration to the patient.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 1-71, wherein the intravenous administration is central intravenous administration.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 1-71, wherein the intravenous administration is peripheral intravenous administration.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 1-73, wherein the patient is an adult human.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 1-73, wherein the patient is a pediatric human.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 1-75, wherein the patient does not suffer from anemia or have reduced blood volume.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 1-75, wherein the patient has at least 95% of the amount of their average daily blood volume.

### Claim 78

An intravenous formulation containing ABDNAZ for intravenous administration to a patient, comprising:
a. whole blood in an amount of at least 60% v/v of the formulation;
b. a polyethylene glycol at a concentration of from about 0.4 μL/mL to about 30 μL/mL in the formulation;
c. N,N-dimethylacetamide at a concentration of from about 0.2 μL/mL to about 15 μL/mL in the formulation;
d. ABDNAZ at a concentration of at least 10 μg/mL in the formulation;
e. water; and
f. an anticoagulant.

### Claim 79 (depends on 78)

The intravenous formulation of claim 78, wherein the formulation consists essentially of:
a. whole blood in an amount of at least 60% v/v of the formulation;
b. a polyethylene glycol at a concentration of from about 0.4 μL/mL to about 30 μL/mL in the formulation;
c. N,N-dimethylacetamide at a concentration of from about 0.2 μL/mL to about 15 μL/mL in the formulation;
d. ABDNAZ at a concentration of at least 10 μg/mL in the formulation;
e. water; and
f. an anticoagulant.

### Claim 80 (depends on 78)

The intravenous formulation of claim 78, wherein the formulation consists of:
a. whole blood in an amount of at least 60% v/v of the formulation;
b. a polyethylene glycol at a concentration of from about 0.4 μL/mL to about 30 μL/mL in the formulation;
c. N,N-dimethylacetamide at a concentration of from about 0.2 μL/mL to about 15 μL/mL in the formulation;
d. ABDNAZ at a concentration of at least 10 μg/mL in the formulation;
e. water; and
f. an anticoagulant.

### Claim 81 (depends on 78, 79, 80, 81)

The intravenous formulation of any one of claims 78-81, wherein the polyethylene glycol is a polyethylene glycol having a number average molecular weight in the range of about 200 g/mol to about 600 g/mol.

### Claim 82 (depends on 78, 79, 80, 81)

The intravenous formulation of any one of claims 78-81, wherein the polyethylene glycol is a polyethylene glycol having a number average molecular weight of about 400 g/mol.

### Claim 83 (depends on 78, 79, 80, 81, 82)

The intravenous formulation of any one of claims 78-82, wherein the anticoagulant comprises one or more of heparin and a citrate salt.

### Claim 84 (depends on 78, 79, 80, 81, 82)

The intravenous formulation of any one of claims 78-82, wherein the anticoagulant is a solution comprising an alkali metal citrate salt, dextrose, and water.

### Claim 85 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 20 μg/mL.

### Claim 86 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 50 μg/mL.

### Claim 87 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 100 g/mL.

### Claim 88 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration of at least 150 μg/mL.

### Claim 89 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 1 mg/mL.

### Claim 90 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 0.5 mg/mL.

### Claim 91 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 10 μg/mL to about 250 μg/mL.

### Claim 92 (depends on 78, 79, 80, 81, 82, 83, 84)

The intravenous formulation of any one of claims 78-84, wherein the ABDNAZ formulation contains ABDNAZ at a concentration in the range of about 20 μg/mL to about 200 μg/mL.

### Claim 93 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes at least 60% wt/wt of the formulation.

### Claim 94 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes at least 75% wt/wt of the formulation.

### Claim 95 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes at least 90% wt/wt of the formulation.

### Claim 96 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes from about 60% wt/wt to about 99% wt/wt of the formulation.

### Claim 97 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes from about 70% wt/wt to about 95% wt/wt of the formulation.

### Claim 98 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92)

The intravenous formulation of any one of claims 78-92, wherein the whole blood constitutes from about 75% wt/wt to about 90% wt/wt of the formulation.

### Claim 99 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The intravenous formulation of any one of claims 78-98, wherein there is from about 90 mL to about 110 mL of whole blood in the formulation.

### Claim 100 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The intravenous formulation of any one of claims 78-98, wherein there is from about 95 mL to about 105 mL of whole blood in the formulation.

### Claim 101 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The intravenous formulation of any one of claims 78-98, wherein there is about 100 mL of whole blood in the formulation.

### Claim 102 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

The intravenous formulation of any one of claims 78-98, wherein there is about 10 mL to about 20 mL of whole blood in the formulation.

### Claim 103 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 50 mL to about 200 mL.

### Claim 104 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 75 mL to about 150 mL.

### Claim 105 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 90 mL to about 140 mL.

### Claim 106 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 100 mL to about 140 mL.

### Claim 107 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 100 mL to about 120 mL.

### Claim 108 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102)

The intravenous formulation of any one of claims 78-102, wherein the formulation is in the form of a unit dose having a volume in the range of about 10 mL to about 30 mL.

### Claim 109 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The intravenous formulation of any one of claims 78-108, wherein the polyethylene glycol is present at a concentration of from about 0.4 μL/mL to about 4 μL/mL in the formulation.

### Claim 110 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108)

The intravenous formulation of any one of claims 78-108, wherein the N,N-dimethylacetamide at a concentration of from about 0.2 μL/mL to about 2 μL/mL in the formulation.

### Claim 111 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110)

The intravenous formulation of any one of claims 78-110, wherein the formulation is characterized by the feature that any pain experienced by the patient at the site of intravenous administration due to intravenous administration of the formulation to the patient at a rate in the range of 10 mL/hour to 50 mL/hour is no greater than Grade 2.

### Claim 112 (depends on 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111)

The intravenous formulation of any one of claims 78-111, wherein the formulation is characterized by the feature that any pain experienced by the patient at the site of intravenous administration due to intravenous administration of the formulation to the patient at a rate in the range of 10 mL/hour to 50 mL/hour is no greater than Grade 1.
